Development pathways for subcutaneous formulations of biologics versus biosimilar development

References

• Sekhon BP, Saluja V. Biosimilars: an overview. Biosimilars. 2011;1:1–11.
   Google Scholar
• Liu HF, Ma J, Winter C, et al. Recovery and purification process development for monoclonal antibody production. mAbs. 2010;2(5):480–499.
   PubMed Web of Science ®Google Scholar
• Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with post-translational modifications. J Immunol Res. 2016;2016:1298473.
   PubMed Web of Science ®Google Scholar
• Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2017;56(suppl_4):iv14–iv29.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–1334.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process - Q5E: 2004. [updated 2004 Nov 18]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf.
   Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–318.
   PubMed Web of Science ®Google Scholar
• Vezer B, Buzas Z, Sebeszta M, et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016;32(5):829–834.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process: non-clinical and clinical issues: 2007 [ updated 2007 Jul 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf.
   Google Scholar
• Food and Drug Administration. Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process: 2005. [updated 2005 Jun]. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm073476.pdf.
   Google Scholar
• Dychter SS, Gold DA, Haller MF. Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs. 2012;35(3):154–160.
   PubMedGoogle Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–842.
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425–440.
   PubMed Web of Science ®Google Scholar
• Jackisch C, Muller V, Maintz C, et al. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74(4):343–349.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky MA, et al. Two-year efficacy and safety of subcutaneous tocilizumab in combination with disease-modifying antirheumatic drugs including escalation to weekly dosing in rheumatoid arthritis. J Rheumatol. 2018;45(4):456–464.
   PubMed Web of Science ®Google Scholar
• Mehr SR, Zimmerman MP. Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits. 2016;9(9):515–518.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Assessment report - Herceptin (EMA/CHMP/751770/2012/corr1): 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000278/WC500153233.pdf.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Assessment report MabThera SC (EMA/CHMP/71722/2014): 2014. [EPAR Basis for approval in NHL]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000165/WC500168097.pdf.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Assessment report MabThera SC (EMA/276108/2016): 2016. [EPAR, basis for approval in CLL]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000165/WC500208542.pdf.
   Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210–2231.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Muller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979–1987.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. US prescribing information RITUXAN HYCELA: 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf.
   Google Scholar
• Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9(12):1035–1050.
   PubMed Web of Science ®Google Scholar
• Leveque D. Subcutaneous administration of anticancer agents. Anticancer Res. 2014;34(4):1579–1586.
   PubMed Web of Science ®Google Scholar
• Roche Registration Ltd. Herceptin® (trastuzumab). Summary of Product Characteristics [cited 2016 Sept]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf
   Google Scholar
• Roche Registration Ltd. MabThera - Summary of product characteristics: 2017. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
   Google Scholar
• Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28(10):509–516.
   PubMed Web of Science ®Google Scholar
• Pimentel FF, Morgan G, Tiezzi DG, et al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceut Med. 2018;32(5):319–325.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15(3):343–352.
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–e138.
   PubMed Web of Science ®Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32(17):1782–1791.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–e82.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR MabThera EMA/276108/2016: procedural steps taken and scientific information after the authorisation: 2016 [updated 2016 Aug 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000165/WC500025820.pdf.
   Google Scholar
• European Medicines Agency. EPAR MabThera EMA/CHMP/71722/2014: procedural steps taken and scientific information after the authorisation. 2014. Available from: https://www.ema.europa.eu/documents/procedural-steps-after/mabthera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf.
   Google Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957.
   PubMed Web of Science ®Google Scholar
• Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053–1058.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev1): 2014. [ updated 2014 Dec 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf.
   Google Scholar
• Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product: 2015 [ updated 2015 Apr]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf%202.%20Clinical%20Immunogenicity%20Assessment3.
   Google Scholar
• European Medicines Agency. Guideline on similar biological products (CHMP/437/04 Rev 1): 2014 [ updated 2014 Oct 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
   Google Scholar
• Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017. 18(7):917–928.
   Web of Science ®Google Scholar
• von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018. 19(7):987–998.
   Web of Science ®Google Scholar
• Kang HN, Knezevic I. Regulatory evaluation of biosimilars throughout their product life-cycle. Bull World Health Organ. 2018;96(4):281–285.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Yoo D, Jaworski J. THU0191 Novel formulation of ct-p13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase i/iii randomised controlled trial. Ann Rheum Dis. 2018;77:315.
   PubMed Web of Science ®Google Scholar
• Eleryan MG, Akhiyat S, Rengifo-Pardo M, et al. Biosimilars: potential implications for clinicians. Clin Cosmet Investig Dermatol. 2016;9:135–142.
   PubMed Web of Science ®Google Scholar
• Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–372.
   PubMed Web of Science ®Google Scholar
• European Biopharmaceutical Enterprises. Position paper - biosimilarity and comparability after manufacturing changes: can a biologic become a biosimilar of itself? 2016 [ updated 2016 Feb 22]. Available from: http://www.ebe-biopharma.eu/uploads/Modules/Documents/ebe-briefing-biosimilarity-versus-manufacturing-changes-public-2016-02-22-2.pdf.
   Google Scholar
• Rugo HS, Rifkin RM, Declerck P, et al. Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2018.
   Web of Science ®Google Scholar
• European Medicines Agency Biosimilars in the EU - Information guide for healthcare professionals: 2017 [cited 2017 Jul 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
   Google Scholar
• Food and Drug Administration. Biosimilars: new educational materials: 2017. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm.
   Google Scholar
• Lyman GH, Balaban E, Diaz M, et al. American society of clinical oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260–1265.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209–217.
   PubMed Web of Science ®Google Scholar